The Yale Cancer Center Consortium to Advance Equity in Early Phase Clinical Trials
The Yale Cancer Center Consortium to Advance Equity in Early Phase Clinical Trials is a multi-year, multidisciplinary membership opportunity comprised of leading pharmaceutical and biotechnology companies, philanthropic stakeholders, and community leaders working hand-in-hand with Yale clinician-scientists to advance a novel model for clinical trial participation. As this initiative has untapped potential to improve state-of-art accessibility to early phase cancer clinical trials across industry and academic sectors, Yale Cancer Center is seeking a plurality of corporate members for this initiative, which is not exclusive to a single party.
The Consortium has three pillar aims:
- To conduct a multi-level assessment of the unique facilitators and barriers to recruitment of under-represented populations to early phase (Phase Ia/Ib/I with expansion cohorts/limited Phase II) cancer clinical trials, addressing patient, provider, health system, and policy-level influences.
- To implement a sustainable hybrid decentralization clinical trials model which will:
- Increase recruitment of under-represented patients to early phase oncology clinical trials
- Maintain patient safety and data integrity of early phase clinical trials
- To evaluate the patient, provider, and health system experience of the hybrid decentralization model and assess its ability to address barriers to early phase trial inclusion of under-represented patients.
For more information:
Patricia LoRusso, DO
Associate Cancer Center Director for Experimental Therapeutics
Tammy Wu, PhD
Senior Associate Director, Corporate and Foundation Relations
Jessica Lewis, PhD, MFT
Deputy Director, CEHE